This may be a trend. And if so, it’s a troubling one.
On HealthNewsReview.org, we’ve just posted a review of a Wall Street Journal story that we characterize as
“Another story that lets a drug company get away with making superiority claims without releasing data.”
Many news orgs let the makers of Provenge get away with this just a few days ago.
Stock manipulation anyone?
Is it going to kill anyone to wait until the data is actually released when independent expert opinion can be sought?
We don’t like this practice one bit.